Kala Pharmaceuticals Reports Third Quarter 2020 Financial Results and Provides Corporate Update
WATERTOWN, Mass.--(BUSINESS WIRE)--Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye, today reported financial results for the third quarter ended September 30, 2020 and provided a corporate update. “We are pleased with our third quarter results and the fourth quarter of 2020 is off to a strong start following the recent FDA approval of EYSUVIS, which we plan to launch